Hat mitgewirkt an:
-
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
-
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
-
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
-
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis